Justin Darrah

Clinical trials

• Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2026–2038
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2028
• Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2023–2038
• Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

  Sub-investigator · Recruiting · Phase 1

  Joshua Sasine, MD, PhD

  2024–2027